Nova Eye Medical Limited
ELXMF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $16 | $13 | $13 | $10 |
| % Growth | 26.4% | -2% | 30.1% | – |
| Cost of Goods Sold | $6 | $4 | $2 | $9 |
| Gross Profit | $10 | $9 | $11 | $1 |
| % Margin | 63.2% | 66.2% | 85.4% | 13% |
| R&D Expenses | $3 | $1 | $1 | $1 |
| G&A Expenses | $1 | $1 | $1 | $1 |
| SG&A Expenses | $10 | $10 | $8 | $9 |
| Sales & Mktg Exp. | $9 | $9 | $7 | $7 |
| Other Operating Expenses | $0 | $0 | $3 | -$3 |
| Operating Expenses | $12 | $11 | $12 | $7 |
| Operating Income | -$2 | -$3 | -$1 | -$6 |
| % Margin | -10.6% | -21.4% | -6% | -55.3% |
| Other Income/Exp. Net | -$2 | -$3 | -$2 | -$0 |
| Pre-Tax Income | -$4 | -$5 | -$3 | -$6 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$4 | -$5 | -$3 | -$6 |
| % Margin | -22.4% | -41.7% | -24% | -55.5% |
| EPS | -0.014 | -0.024 | -0.015 | -0.029 |
| % Growth | 41.3% | -61% | 49.1% | – |
| EPS Diluted | -0.014 | -0.024 | -0.015 | -0.029 |
| Weighted Avg Shares Out | 265 | 230 | 217 | 196 |
| Weighted Avg Shares Out Dil | 265 | 230 | 218 | 196 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $2 | $0 | $2 | $1 |
| EBITDA | -$2 | -$5 | -$2 | -$4 |
| % Margin | -9.4% | -40.1% | -11.7% | -41.3% |